Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Tax Provisions (2020 - 2026)

Collegium Pharmaceutical has reported Tax Provisions over the past 6 years, most recently at $12.1 million for Q4 2025.

  • For Q4 2025, Tax Provisions rose 155.08% year-over-year to $12.1 million; the TTM value through Dec 2025 reached $29.7 million, up 1.26%, while the annual FY2025 figure was $29.7 million, 1.26% up from the prior year.
  • Tax Provisions for Q4 2025 was $12.1 million at Collegium Pharmaceutical, up from $11.9 million in the prior quarter.
  • Over five years, Tax Provisions peaked at $14.8 million in Q4 2023 and troughed at -$61.9 million in Q2 2021.
  • A 5-year average of $398450.0 and a median of $2.9 million in 2021 define the central range for Tax Provisions.
  • Biggest five-year swings in Tax Provisions: plummeted 25243.09% in 2021 and later soared 6900.76% in 2024.
  • Year by year, Tax Provisions stood at -$13.8 million in 2021, then surged by 95.72% to -$592000.0 in 2022, then skyrocketed by 2594.93% to $14.8 million in 2023, then crashed by 67.96% to $4.7 million in 2024, then surged by 155.08% to $12.1 million in 2025.
  • Business Quant data shows Tax Provisions for COLL at $12.1 million in Q4 2025, $11.9 million in Q3 2025, and $5.0 million in Q2 2025.